Eyelid Margin Inflammation: Pathophysiology, Diagnosis and Management Approaches
DOI:
https://doi.org/10.12775/JEHS.2025.79.58742Keywords
eyelid rim inflammation, Meibomian gland dysfunction, demodexAbstract
Introduction and Purpose: Eyelid margin inflammation is a commonly reported syndrome of ophthalmic complaints. It is a chronic, multifactorial disorder of the eyelid margins that significantly impacts the visual function and quality of life of patients across all age groups. Establishing the epidemiology is challenging, and the diagnosis relies primarily on a physical examination combined with a thorough ophthalmological assessment, potentially supplemented by additional tests. The condition is recurrent, often necessitating long-term treatment. Successful management requires close collaboration between the specialist and the patient, which demands commitment and patience. Eyelid margin inflammation manifests through various symptoms, such as burning, itching, dryness, or a feeling of sand in the eyes. This condition is characterized by a wide range of symptoms with varying severity, contributing to the complexity of its diagnosis and treatment. This review examines the diagnostic approaches and treatment strategies for eyelid margin inflammation, focusing on the most common underlying factors.
Materials and Methods: A comprehensive survey of articles published in scientific journals was conducted via the online research platforms PubMed and Google Scholar. Articles were searched by entering keywords in the appropriate configuration: “eyelid rim inflammation”, “ Meibomian gland dysfunction”, “demodex”.
Description of current knowledge: Studies have indicated that the approach to diagnosing and managing eyelid margin inflammation is largely contingent on the underlying cause and the intensity of the patient's symptoms.
Keywords: “eyelid rim inflammation”, “ Meibomian gland dysfunction”, “demodex”.
References
[1] H. Tanabe, M. Kaido, M. Kawashima, R. Ishida, M. Ayaki, and K. Tsubota, “Effect of Eyelid Hygiene Detergent on Obstructive Meibomian Gland Dysfunction,” Dec. 11, 2018, Japan Oil Chemists’ Society. doi: 10.5650/jos.ess18161.
[2] “Bowman RW, Dougherty JM, McCulley JP. Chronic blepharitis and dry eyes. Int Ophthalmol Clin. 1987; 27(1): 27-35,”
[3] “Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: recent clinical trials. Ocul Surf 2014;12(4):273-84.,”
[4] “Duncan K, Jeng BH. Medical management of blepharitis. Curr Opin Ophthalmol 2015;26(4):289-94.,”
[5] “Bowling B. Eyelids. In: Kanski’s Clinical Ophthalmology. 2016.,”
[6] J. B. del C. Sánchez, “How to promote and preserve eyelid health,” Oct. 01, 2012, Dove Medical Press. doi: 10.2147/opth.s33133.
[7] M. A. Alhamazani, M. Alnabri, M. Alreshidi, H. M. Alsulaiman, D. Strianese, and R. N. Althaqib, “Assessing public awareness of daily eyelid hygiene habits in Saudi Arabia,” Oct. 01, 2021, Elsevier BV. doi: 10.4103/sjopt.sjopt_25_20.
[8] “Karaszewski M., Misiuk-Hojło M., Przeździecka-Dołyk J., Gnus J., Zapalenie brzegów powiek – wszechstronne spojrzenie na powszechne schorzenie, OPHTHATHERAPY Vo l . 7 / Nr 3 (27) / 2020.,”
[9] “Soh Qin R, Tong Hak Tien L. Healthcare delivery in meibomian gland dysfunction and blepharitis. Ocul Surf. 2019; 17(2): 176-8,”
[10] “The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the InternationalDry Eye Workshop (2007). Ocul Surf. 2007; 5(2): 75-92.,”
[11] “Chamaillard M, Mortemousque B, Boralevi F, et al. Cutaneous and ocular signs of childhood rosacea. Arch Dermatol. 2008;144(2):167-171.,”
[12] “Arici MK, Sümer Z, Toker MI et al. The prevalence of Demodex folliculorum in blepharitis patients and the normal population. Ophthalmic Epidemiol. 2005; 12(4): 287-90.,”
[13] S. Sabeti, A. Kheirkhah, J. Yin, and R. Dana, “Management of meibomian gland dysfunction: a review,” Survey of Ophthalmology, vol. 65, no. 2. Elsevier BV, p. 205, Sep. 05, 2019. doi: 10.1016/j.survophthal.2019.08.007.
[14] F. SR, H. JS, J. K. Patel, and O. DL, “Demodex blepharitis: clinical perspectives,” Jul. 01, 2018. Accessed: Dec. 2024. [Online]. Available: https://doaj.org/article/d58303eaa7ec4e8ea692b548c047d55c
[15] J. Liu, H. Sheha, and S. C. G. Tseng, “Pathogenic role of Demodex mites in blepharitis,” Current Opinion in Allergy and Clinical Immunology, vol. 10, no. 5. Lippincott Williams & Wilkins, p. 505, Aug. 04, 2010. doi: 10.1097/aci.0b013e32833df9f4.
[16] “Kheirkhah A, Blanco G, Casas V et al. Fluorescein dye improves microscopic evaluation and counting of Demodex in blepharitis withcylindrical dandruff. Cornea. 2007; 26(6): 697-700,”
[17] “Amescua G, Akpek EK, Farid M et al. Blepharitis Preferred Practice Pattern®. Ophthalmology. 2018; 126: P56-93,”
[18]
“https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/blepharitis,”
[19] “https://my.clevelandclinic.org/health/diseases/10032-blepharitis,”
[20] “https://www.webmd.com/eye-health/blepharitis,”
[21] W. B. Jackson, “Blepharitis: current strategies for diagnosis and management,” Apr. 01, 2008, Elsevier BV. doi: 10.3129/i08-016.
[22] K. Lindsley, S. Matsumura, E. Hatef, and E. K. Akpek, “Interventions for chronic blepharitis,” Cochrane library. Elsevier BV, May 10, 2012. doi: 10.1002/14651858.cd005556.pub2.
[23] N. Din and P. Nn, “Blepharitis — a review of diagnosis and management,” International Journal of Ophthalmic Practice, vol. 3, no. 4. p. 150, Aug. 01, 2012. doi: 10.12968/ijop.2012.3.4.150.
[24] “Lindsley K, Matsumura S, Hatef E et al. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012; (5): CD005556.,” Jan. 01, 1AD.
[25] C. M. Putnam, “Diagnosis and management of blepharitis: an optometrist’s perspective,” Clinical Optometry. Dove Medical Press, p. 71, Aug. 01, 2016. doi: 10.2147/opto.s84795.
[26] “Jones L, Downie LE, Korb D et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017; 15(3): 575-628.,”
[27] “Perry HD, Doshi-Carnevale S, Donnenfeld ED et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatmentof meibomian gland dysfunction. Cornea. 2006; 25(2): 171-5. ,”
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Grzegorz Szcześniak, Aleksandra Kiełczewska, Anna Kiełczewska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 13
Number of citations: 0
